On April 27, 2022, after the market closed, SQZ Biotechnologies (NYSE: SQZ) announced that the FDA granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
The Fast Track Designation potentially allows SQZ to sell its SQZ Antigen Presenting Cells product candidate to patients earlier and accelerate the development and review of treatments for serious and life-threatening diseases where no treatment currently exists or where the treatment in discovery may be better than what is currently available.
